Immunotherapy of inflammatory demyelinating diseases of the central nervous system

Immunologic Research

Volumn 23, Issue 2-3, 2001, Pages 245-252

  Bright, J J ^a   Sriram, S ^a  

^a Vanderbilt Stallworth Rehabilitation Hospital   (United States)

Author keywords

Autoimmunity; Central Nervous System; Demyelination; Experimental Allergic Encephalitis; Multiple Sclerosis; Signaling; Transforming Growth Factor

Indexed keywords

GLATIRAMER; LISOFYLLINE; TRANSFORMING GROWTH FACTOR BETA; TYRPHOSTIN;

ALLERGIC ENCEPHALITIS; ARTICLE; CENTRAL NERVOUS SYSTEM; DEMYELINATING DISEASE; DRUG MECHANISM; DRUG POTENCY; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WHITE MATTER;

ADULT; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CD4-POSITIVE T-LYMPHOCYTES; CEREBROSPINAL FLUID; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CYTOKINES; DEMYELINATING AUTOIMMUNE DISEASES, CNS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INTERLEUKIN-12; MICE; MULTIPLE SCLEROSIS; PENTOXIFYLLINE; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034983701     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:23:2-3:245     Document Type: Article

References (45)

1. Immunologic aspects of neurologic disease
2. Assessment of animal models of MS and demyelinating disease in the designs of rational therapy
3. Animal models of myasthenia gravis
4. Eighty three years of the Guillain-Barre syndrome: Clinical and immunopathologic aspects, current and future treatments
5. Pathogenesis of Guillain-Barre syndrome
6. Animal models for autoimmune demyelinating disorders of the nervous system
7. Pathogenesis of disease mediated by HTLV-1 infection
8. The distinction blurs between an autoimmune versus microbial hypothesis in MS
9. Progress in determining the causes and treatment of multiple sclerosis
10. Multiple sclerosis
11. Multiple sclerosis
12. The natural history of MS;a geographically based study. Predictive value of early clinical course
13. Immunology of demyelinating disease
14. Epidemiologic evidence for MS as an infection
15. EAE and autoimmunity
16. The immunology of MS and of its animal model, EAE
17. Genetic models of CNS inflammation
18. MHC class II molecules and autoimmunity
19. Virus induced autoimmunity: Molecular mimicry as a route to autoimmune disease
20. Molecular mimicry in T cell mediated autoimmunity: Viral peptides activate human T cell clones specific for MBP
21. Repeated treatment with chimeric anti-CD4 antibody in MS
22. Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS
23. The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis
24. Interleukin 12: A pro-inflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity
25. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalomyelitis
26. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin-12
27. Interleukin-12: Amiss in MS
28. Elevated Serum levels of IL-12 in chronic progressive MS
29. Transforming growth factor-β: Biological function and chemical structure
30. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-beta1
31. Regulation of microglial activation by TGF-β, IL-10 and CSF-1
32. TGF-β inhibits IL-12-induced activation of Jak-Star pathway in T lymphocytes
33. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
34. TGF-β inhibits IL-2 induced tyrosine phosphorylation and activation of Jak-1 and Stat 5 in T lymphocytes
35. Downregulation of interleukin-12 (IL-12) responsiveness in human T cells by transforming growth factor-beta: Relationship with IL-12 signaling
36. Resolving conflicting signals: Cross inhibition of cytokine signaling pathways
37. Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak-2 kinase and Stat 1 nuclear factor
38. TGF-β suppression of IFN-gamma induced class II MHC gene expression does not involve inhibition of phosphorylation of Jak-1, Jak-2 or signal transducers and activators of transcription, or modification of IFN-gamma enhanced factor X expression
39. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice
40. Lisofylline abrogates the cytotoxic drug-induced ex vivo release of hematopoietic inhibitors by routine spleen cells
41. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline
42. Tyrphostins: Tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction
43. Tyrphostin AG497 blocks Cdk2 activation
44. Effect of protein tyrosine kinase inhibitors on the replication of herpes simplex virus and the phosphorylation of viral proteins
45. Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of JAK-2 kinase and prevent experimental allergic encephalomyelitis